The notification indicates a GST demand of ₹33.66 crore, an interest charge of ₹18.18 crore, and a penalty amounting to ₹3.37 crore, resulting in a total financial impact of approximately ₹55.20 crore.
Also Read: Max Healthcare to acquire Yerawada Properties, invest ₹1,020 crore to set up 450-bed hospital in Pune
The company is actively pursuing rectification of the notification. Should the outcome be unfavorable, Max Healthcare may consider filing an appeal with the relevant authority. The management has noted that the final decision of the proceedings could affect financial results depending on the resolution.Second Quarter Results
Max Healthcare Institute reported a net profit of ₹491 crore for the September quarter, reflecting a 74.3% increase from ₹282 crore in the same period last year. Quarterly revenue rose 25% year-on-year to ₹2,135 crore from ₹1,707 crore in Q2 FY25, primarily due to an uptick in outpatient department (OBD) visits.
EBITDA surged 17.5% to ₹575 crore, compared to ₹451 crore a year prior. The EBITDA margin saw a slight improvement, rising to 26.9% from 26.4% in the same quarter of the previous year. International patient revenue reached ₹231 crore, marking a 25% YoY increase and an 11% QoQ rise, contributing to approximately 9% of total hospital revenue.
Also Read: Max Healthcare Q1 Results: Shares fall as earnings miss expectations
The overall EBITDA per bed for Q2 FY26 was ₹73.4 lakh, in contrast to ₹71.2 lakh in Q2 FY25 and ₹68.5 lakh in Q1 FY26. For existing units, the EBITDA per bed was ₹76.5 lakh, demonstrating a 7% YoY growth.
Shares of Max Healthcare Institute Ltd concluded the day at ₹1,046.60, down by ₹17.50, or 1.64%, on the BSE.
